Blood Clotting Factors Market Analysis & Forecast: 2026-2033
The Blood Clotting Factors Market size is anticipated to grow at a CAGR of 8.8% with USD 7.43 Bn in 2026 and is expected to reach USD 13.42 Bn in 2033. The primary drivers are defined by the increasing diagnosis of hemophilia and von Willebrand disease, wider adoption of prophylactic therapy, improved treatment access, and development of recombinant and extended-half-life clotting factors. According to the World Federation of Hemophilia, its latest Annual Global Survey reported a 6% increase in the global identification of people with hemophilia, indicating a growing diagnosed treatment population. This is strengthening demand for factor VIII, factor IX, von Willebrand factor, bypassing agents, and other replacement therapies across hospitals, hemophilia treatment centers, specialty clinics, and home-care settings globally.
On the basis of product type, the Factor VIII segment is projected to account for the largest Blood Clotting Factors Market share of 48.5% in 2026. The segment’s growth is owing to the replacement requirements in patients with hemophilia A, particularly those with severe disease.
The FDA defines severe hemophilia as clotting-factor activity below 1%, a level associated with bleeding risk and prophylactic treatment demand. CDC data also indicate that approximately 1 in 5 people with hemophilia may develop an inhibitor during their lifetime, complicating conventional factor therapy and increasing the need for Factor VIII management, monitoring, and dosing strategies.
In June 2024, the European Commission authorized ALTUVOCT, an extended-half-life Factor VIII replacement therapy for patients of all ages with hemophilia A. The EMA states that ALTUVOCT is administered once weekly, compared with injections every two to four days for many authorized Factor VIII prophylactic products, improving convenience and potentially supporting adherence.
To learn more about this report, Request Free Sample
On the basis of application, the haemophilia segment lead with a major 72.8% share in 2026. The growth is owing to the lifelong demand for factor VIII and factor IX replacement, routine prophylaxis, perioperative management, and treatment of breakthrough bleeding.
The CDC reports that about one-third of babies diagnosed with haemophilia have no known family history, thereby highlighting the emergence of newly identified patients requiring treatment.
In September 2025, Novo Nordisk submitted a Biologics License Application to the FDA for Mim8, an investigational prophylactic therapy for hemophilia A with or without inhibitors. If approved, Mim8 would provide weekly, biweekly, or monthly dosing through a prefilled pen.
The U.S. Blood Clotting Factors Market is undergoing a transition from episodic treatment toward individualized prophylaxis, extended half-life replacement therapy, and expanded indications covering broader patient age groups. Recombinant Factor VIII and Factor IX products allow clinicians to maintain higher trough-factor levels with fewer infusions. This may reduce treatment burden, improve adherence, and support the greater use of prophylaxis among children as well as adults.
In July 2026, the FDA issued an additional approval letter for WILATE, a human von Willebrand factor and coagulation Factor VIII complex manufactured by Octapharma. The FDA’s current indication includes on-demand treatment, perioperative bleeding management, and routine prophylaxis in adult and pediatric patients with von Willebrand disease. WILATE is also indicated for treatment and prophylaxis in patients aged 12 years and older with hemophilia A. The approval strengthens the availability of plasma-derived VWF/FVIII therapy across multiple inherited bleeding-disorder applications.
Extended half-life recombinant Factor VIII represents one of the most important technological advances in the Blood Clotting Factors Market. Conventional Factor VIII products may require intravenous administration several times per week because Factor VIII is rapidly cleared from circulation. Extended half-life products use technologies such as Fc fusion, PEGylation, albumin fusion, and von Willebrand factor–binding modifications to extend circulation time and maintain therapeutic factor activity.
In February 2023, Sanofi announced the FDA approval of ALTUVIIIO, a once-weekly factor VIII therapy for adults and children with hemophilia A. The treatment sustains near-normal factor activity for most of the week and substantially reduces bleeding compared with prophylactic therapies.
|
Current Event |
Description and its Impact |
|
2026 Medicare Clotting-Factor Furnishing Fee Update in the U.S.
|
|
|
EU Substances of Human Origin Regulation and Plasma-Supply Requirements |
|
Uncover macros and micros vetted on 75+ parameters: Get instant access to report
To learn more about this report, Request Free Sample
The North America region accounts for 58.2% of the market share in 2026. The region’s growth is owing to treated population, comprehensive specialty care, reimbursement coverage, and product innovation.
CDC’s March 2024 profile identifies 139 hemophilia treatment centers across the United States and its territories, strengthening diagnosis, factor-level monitoring, inhibitor testing, and coordinated long-term care. CMS confirms that Medicare Part B covers blood clotting factors for eligible patients with factor VIII deficiency, factor IX deficiency, and von Willebrand disease, thereby supporting the treatment access.
In July 2025, Novo Nordisk announced FDA approval expanding Alhemo as a once-daily prophylactic treatment for patients aged 12 years and older with hemophilia A or B without inhibitors. The subcutaneous therapy significantly reduces bleeding rates and broadens treatment options.
Asia Pacificis expected to witness strong growth in Blood Clotting Factors Market over the forecast period. The region’s growth is owing to large diagnosed population, wider prophylaxis access, and continued development of factor-replacement and gene-based therapies.
India’s Ministry of Health reported an estimated haemophilia caseload of 136,000, underscoring unmet need for Factor VIII, Factor IX, and bypassing products. Australia’s Therapeutic Goods Administration cited 3,127 people living with haemophilia A or B in the national registry, indicating sustained demand for recombinant and plasma-derived clotting factors.
In February 2026, Karnataka launched Kusuma Sanjeevini which provides free monthly emicizumab prophylaxis for haemophilia patients through 36 treatment centres. The programme targets about 1,000 patients, thereby aiming to prevent bleeding, reduce complications, as well as improve access to continuous preventive care across Karnataka.
The United States Blood Clotting Factors Market is driven by the diagnosed haemophilia population, broader prophylaxis use, treatment centres, and innovation in bleeding prevention. The CDC reports that 15%–20% of people with inherited haemophilia A or B develop inhibitors that prevent replacement clotting factors from working effectively. This is increasing the demand for alternative factor products, bypassing agents, and monitoring services.
In March 2025, the FDA approved Qfitlia (fitusiran) for routine prophylaxis in patients aged 12 years and older with haemophilia A or B, with or without factor inhibitors. Its once-monthly or once-every-two-months dosing expands treatment choice and encourages competition, adoption, and investment in the United States haemophilia treatment ecosystem.
China is emerging as a high-growth country for Blood Clotting Factors owing to the haemophilia population, unmet access needs, and expanding domestic biologics capacity. The official NHSA materials record 27,689 registered haemophilia patients nationwide in 2022, thereby highlighting the sustained demand for factor VIII, factor IX, and bypassing therapies.
In March 2026, Belief BioMed and Grand Life Sciences formed an exclusive commercialization partnership for BBM-H803 across Greater China. The collaboration combines gene-therapy development and commercialization capabilities to accelerate patient access to this investigational hemophilia A treatment.
Some of the major key players in Blood Clotting Factors Market are Shire Plc, Baxter International Inc., Grifols International SA, Roche AG, Bayer AG, Pfizer Inc., Novo Nordisk A/S, Octapharma AG, Biogen Idec, and Kedrion S.P.A.
| Report Coverage | Details | ||
|---|---|---|---|
| Base Year: | 2025 | Market Size in 2026: | USD 7.43 Bn |
| Historical Data for: | 2020 To 2024 | Forecast Period: | 2026 To 2033 |
| Forecast Period 2026 to 2033 CAGR: | 8.8% | 2033 Value Projection: | USD 13.42 Bn |
| Geographies covered: |
|
||
| Segments covered: |
|
||
| Companies covered: |
Shire Plc, Baxter International Inc., Grifols International SA, Roche AG, Bayer AG, Pfizer Inc., Novo Nordisk A/S, Octapharma AG, Biogen Idec, and Kedrion S.P.A. |
||
| Growth Drivers: |
|
||
| Restraints & Challenges: |
|
||
Uncover macros and micros vetted on 75+ parameters: Get instant access to report
Share
Share
Abhijeet Kale is a results-driven management consultant with five years of specialized experience in the biotech and clinical diagnostics sectors. With a strong background in scientific research and business strategy, Abhijeet helps organizations identify potential revenue pockets, and in turn helping clients with market entry strategies. He assists clients in developing robust strategies for navigating FDA and EMA requirements.
Joining thousands of companies around the world committed to making the Excellent Business Solutions.
View All Our Clients
